Nasdaq:US$11.88 (+0.00) | HKEX:HK$19.10 (+0.12) | AIM:£1.91 (-0.05)
上一篇文章   |   下一篇文章
公告及新闻稿, 监管通知 | 2015-04-16

Director’s Shareholding

London: Thursday, 16 April 2015: Chi-Med received notification on 16 April 2015 that Simon To, Executive Director and Chairman, has purchased 28,000 ordinary shares of US$1.00 each in Chi-Med (the “Shares”) at a price of GBP15.85 per share on 15 April 2015. Following this purchase, Mr To is beneficially interested in 180,000 Shares, representing approximately 0.34% of the current issued share capital of Chi-Med.



Telephone: +852 2121 8200
Christian Hogg, CEO

Panmure Gordon (UK) Limited
Telephone: +44 20 7886 2500
Richard Gray
Andrew Potts

Citigate Dewe Rogerson
Telephone: +44 20 7638 9571
Anthony Carlisle Mobile: +44 7973 611 888
David Dible Mobile: +44 7967 566 919

About Chi-Med
Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: